參考文獻(xiàn)/References:
[1] 張健,呂守正,劉英春,等.156例頸性眩暈患者病因分析及治療探討[J].當(dāng)代醫(yī)學(xué),2012,18(15):83-84.
[2] HANNECKE V,MAYOUX-BENHAMOU MA,BONNICHON P,et al.Metabolic differentiation of the human longus colli muscle[J].Morphologie,2001,85(269):9-12.
[3] 宋敏,蔣宜偉,史達(dá).椎動(dòng)脈型頸椎病發(fā)病機(jī)制研究進(jìn)展[J].頸腰痛雜志,2003,24(5):310-312.
[4] 董志鋒,任春貞.頸椎病治療的研究進(jìn)展[J].世界最新醫(yī)學(xué)信息文摘,2018,18(16):105.
[5] 仲衛(wèi)紅,馮居平,陳水金,等.福州市中青年伏案工作者頸椎病的流行病學(xué)調(diào)查及危險(xiǎn)因素的研究[J].中國(guó)中醫(yī)骨傷科雜志,2010,18(2):50-51.
[6] 葉秀蘭,謝興文,李寧,等.從肝、脾、腎論治頸椎病——施杞教授治療頸椎病學(xué)術(shù)思想之一[J].中國(guó)中醫(yī)骨傷科雜志,2005,26(4):46-47.
[7] 董萬(wàn)濤,宋敏,鄧強(qiáng).從虛痰瘀論治椎動(dòng)脈型頸椎病探析[J].甘肅中醫(yī),2008,21(2):2-4.
[8] 汪小敏,曹林忠,宋敏,等.從痰論治激素性股骨頭壞死OPG/RANK/RANKL信號(hào)調(diào)控機(jī)制研究進(jìn)展[J].中國(guó)中醫(yī)藥信息雜志,2017,24(10):133-136.
[9] 李力,王振興,王一童,等.朱丹溪眩暈證治探析[J].成都中醫(yī)藥大學(xué)學(xué)報(bào),2017,40(2):96-98.
[10] 盧紅蓉,杜松,胡鏡清.痰瘀互結(jié)證治理論源流考[J].中醫(yī)雜志,2015,56(10):811-815.
[11] 吳玉婷,周迎春.冠心病從痰論治的現(xiàn)代理論研究[J].中國(guó)中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志, 2017,23(7):1029-1031.
[12] 劉鵬,鄭爽,毛旭東,等.楊松濤教授治療項(xiàng)痹臨床經(jīng)驗(yàn)[J].亞太傳統(tǒng)醫(yī)藥,2016,12(16):105-106.
[13] 宋莉娟.化痰清眩丸聯(lián)合氟桂利嗪治療眩暈(痰濕中阻)隨機(jī)平行對(duì)照研究[J].實(shí)用中醫(yī)內(nèi)科雜志,2018,32(2):38-40.
[14] 劉興祥,劉陽(yáng).中醫(yī)痰病學(xué)的現(xiàn)代研究思路與方法探討[J].內(nèi)蒙古中醫(yī)藥,2016,35(14):158-159.
[15] BARQUÍN N,CHOU P,RAMOS C,et al.Increased expression of intercellular adhesion molecule 1,CD11/CD18 cell surface adhesion glycoproteins and alpha 4 beta 1 integrin in a rat model of chronic interstitial lung fibrosis[J].Pathobiology,1996,64(4):187-192.
中醫(yī)正骨2018年8月第30卷第8期 J Trad Chin Orthop Trauma,2018,Vol.30,No.8(總605)
(總606)中醫(yī)正骨2018年8月第30卷第8期 J Trad Chin Orthop Trauma,2018,Vol.30,No.8
[16] 馬青,唐民科,孫文燕.血管性癡呆中醫(yī)發(fā)病機(jī)制現(xiàn)代研究述要[J].中華中醫(yī)藥雜志,2018,33(1):212-215.
[17] LIEN EC,LYSSIOTIS CA,CANTLEY LC.Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer[J].Recent Results Cancer Res,2016,207:39-72.
[18] ULICI V,HOENSELAAR KD,GILLESPIE JR,et al.The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation[J].BMC Dev Biol,2008,8(1):40.
[19] SOUMYA SJ,BINU S,HELEN A,et al.15(S)-HETE-induced angiogenesis in adipose tissue is mediated through activation of PI3K/Akt/mTOR signaling pathway[J].Biochem Cell Biol,2013,91(6):498-505.
[20] 童秀冰,鄭佳璇,廖軍,等.電針對(duì)頸椎病大鼠椎間盤軟骨細(xì)胞及PI3K/Akt信號(hào)通路的影響[J].中國(guó)中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2016,22(9):1232-1235.
[21] VANHAESEBROECK B,GUILLERMET-GUIBERT J,GRAUPERA M,et al.The emerging mechanisms of isoform-specific PI3K signalling[J].Nat Rev Mol Cell Biol,2010,11(5):329-341.
[22] AKINLEYE A,AVVARU P,FURQAN M,et al.Phosphatidylinositol 3-kinase(PI3K)inhibitors as cancer therapeutics[J].J Hematol Oncol,2013,6(1):88.
[23] 夏田.PI3K/AKT信號(hào)通路在ARC保護(hù)細(xì)胞氧化損傷中的作用機(jī)制研究[D].武漢:華中農(nóng)業(yè)大學(xué),2015.
[24] XUE G,HEMMINGS BA.PKB/Akt-dependent regulation of cell motility[J].J Natl Cancer Inst,2013,105(6):393-404.
[25] FRANCIPANE MG,LAGASSE E.mTOR pathway in colorectal cancer:an update[J].Oncotarget,2014,5(1):49-66.
[26] TAKEUCHI CS,KIM BG,BLAZEY CM,et al.Discovery of a novel class of highly potent,selective,ATP-competitive,and orally bioavailable inhibitors of the mammalian target of rapamycin(mTOR)[J].J Med Chem,2013,56(6):2218-2234.
[27] ZHANG W,WANG J,WANG H,et al.Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway[J].Arterioscler Thromb Vasc Biol,2010,30(5):1000-1006.
[28] 鞏彥龍,宋敏,劉濤,等.miRNA與血管新生相關(guān)細(xì)胞因子的研究進(jìn)展[J].臨床心血管病雜志,2016,32(9):877-881.
[29] DAI J,RABIE AB.VEGF:an essential mediator of both angiogenesis and endochondral ossification[J].J Dent Res,2007,86(10):937-950.
[30] TOLOSA L,MIR M,ASENSIO VJ,et al.Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase[J].J Neurochem,2008,105(4):1080-1090.
[31] DALE-NAGLE EA,SATRIOTOMO I,MITCHELL GS.Spinal vascular endothelial growth factor induces phrenic motor facilitation via extracellular signal-regulated kinase and Akt signaling[J].J Neurosci,2011,31(21):7682-7690.
[32] SUN Y,JIN K,XIE L,et al.VEGF-induced neuroprotection,neurogenesis,and angiogenesis after focal cerebral ischemia[J].J Clin Invest,2003,111(12):1843-1851.
[33] ABEYRATHNA P,SU Y.The critical role of Akt in cardiovascular function[J].Vascul Pharmacol,2015,74:38-48.
[34] 向洪斌.疏血通注射液治療椎動(dòng)脈型頸椎病的臨床療效觀察[J].實(shí)用心腦肺血管病雜志,2013,21(7):52-53.
[35] ZIRAN BH,PINEDA S,POKHARNA H,et al.Biomechanical, radiologic, and histopathologic correlations in the pathogenesis of experimental intervertebral disc disease[J].Spine(Phila Pa 1976),1994,19(19):2159-2163.
[36] CANTLEY LC.The phosphoinositide 3-kinase pathway[J].Science,2012,296(5573):1655.
[37] GUSTIN JA,OZES ON,AKCA H,et al.Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation[J].J Biol Chem,2004,279(3):1615-1620.[38] 王羽豐,楊一帆,林定坤,等.應(yīng)用多維數(shù)據(jù)分析規(guī)范頸性眩暈的中醫(yī)辨證規(guī)律[J].山東醫(yī)藥,2011,51(36):106-107.
[39] 潘曄,殷佳,蔡雪朦,等.基于PI3K/Akt信號(hào)通路探討中醫(yī)藥治療冠心病的研究進(jìn)展[J].中草藥,2017,48(19):4100-4104.
[40] 黃小波,王寧群,陳玉靜,等.陳皮、半夏對(duì)衰老臍靜脈內(nèi)皮細(xì)胞中PI3K-Akt和磷酸化p38表達(dá)的影響[J].北京中醫(yī)藥,2016,35(5):411-414.
[41] 丁珊珊,康潔,張凌媛,等.二陳湯對(duì)脂代謝紊亂小鼠Cav-1和PI3K/AKT表達(dá)的影響[J].中華中醫(yī)藥雜志,2017,32(1):242-244.
[42] 石月萍,楊關(guān)林.栝樓薤白半夏湯預(yù)處理保護(hù)缺血再灌注大鼠心肌PI3K/Akt通路機(jī)制[J].中國(guó)中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2016,22(7):906-908.
[43] 韓嵐,梁杰,張艷艷,等.桃紅四物湯對(duì)產(chǎn)后血瘀大鼠血清NO、子宮組織VEGF的表達(dá)及對(duì)PI3K/Akt信號(hào)通路的影響[J].中華中醫(yī)藥雜志,2016,31(5):1625-1629.
[44] 呂卓,孫玲玲,林麗珠.基于VEGF相關(guān)信號(hào)通路研究益氣除痰方對(duì)缺氧血管新生的影響[J].遼寧中醫(yī)雜志,2018,45(4):797-800.
[45] 吳旭彤,朱萱萱,李七一,等.中藥對(duì)血管內(nèi)皮細(xì)胞損傷的保護(hù)作用的研究進(jìn)展[J].中華中醫(yī)藥學(xué)刊,2011,29(12):2648-2650.
相似文獻(xiàn)/References:
[1]孫獻(xiàn)武,于香蘭,邵海燕,等.應(yīng)用三維動(dòng)靜態(tài)平衡康復(fù)模式治療
非脊髓型頸椎病的臨床研究[J].中醫(yī)正骨,2015,27(11):8.
SUN Xianwu,YU Xianglan,SHAO Haiyan,et al.Clinical study on three-dimensional dynamic and static equilibrium rehabilitation modality in the treatment of non-myelopathy type cervical spondylosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):8.
[2]江建春.神經(jīng)根型頸椎病的中醫(yī)藥治療研究概況[J].中醫(yī)正骨,2015,27(11):71.
[3]韋英成,董彤,吳肖梅,等.推拿手法治療神經(jīng)根型頸椎病的研究進(jìn)展[J].中醫(yī)正骨,2015,27(10):65.
[4]張莉,秦丹霞,張細(xì)姣.Orem自理理論在前路手術(shù)治療脊髓型頸椎病
圍手術(shù)期護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2015,27(09):75.
[5]邸保林,董國(guó)順,林紅猛.俯臥斜扳法治療神經(jīng)根型頸椎病[J].中醫(yī)正骨,2015,27(07):70.
[6]白玉,王愛國(guó).郭春園教授治療頸椎病的學(xué)術(shù)思想探究[J].中醫(yī)正骨,2015,27(02):64.
[7]郝慶英,劉楚吟,付嬋娟,等.Hybrid手術(shù)治療脊髓型頸椎病的護(hù)理[J].中醫(yī)正骨,2015,27(02):78.
[8]王翔,詹紅生,張明才,等.石氏手法治療神經(jīng)根型頸椎病的療效觀察[J].中醫(yī)正骨,2015,27(04):12.
WANG Xiang,ZHAN Hongsheng,ZHANG Mingcai,et al.Observation on the curative effect of Shi's manipulation in the treatment of cervical spondylotic radiculopathy[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[9]史俊德,梁舒涵,海淵.毛書歌教授治療寰樞關(guān)節(jié)錯(cuò)縫的經(jīng)驗(yàn)[J].中醫(yī)正骨,2015,27(04):76.
[10]王樹強(qiáng),楊振國(guó),劉文斌,等.董建文教授治療神經(jīng)根型頸椎病的經(jīng)驗(yàn)[J].中醫(yī)正骨,2015,27(01):69.
[11]泮金亮.淺議椎動(dòng)脈型頸椎病的診斷標(biāo)準(zhǔn)[J].中醫(yī)正骨,2016,28(08):76.